Evaluation of antibodies against a rubella virus neutralizing domain for determination of immune status
- PMID: 11063507
- PMCID: PMC95994
- DOI: 10.1128/CDLI.7.6.964-966.2000
Evaluation of antibodies against a rubella virus neutralizing domain for determination of immune status
Abstract
The protective immune responses against rubella virus (RV) are related to its neutralizing epitopes, an issue that is important to consider when assessing the immune status of patients with remote infection. In the present paper, we compare the antibodies detected by a synthetic-peptide-based enzyme immunoassay (EIA) with antibodies detected by the traditional technique of hemagglutination inhibition (HIA) in patients with remote RV infection. The synthetic peptide used as an antigen (SP15) represents a neutralizing epitope that corresponds to amino acids 208 to 239 of the E1 glycoprotein. The SP15-EIA was developed, all variables that affected the assay were standardized, and the test was validated using reference sera. Serum samples (n = 129) from patients with remote RV infection were tested by HIA and SP15-EIA. Discrepant sera were assayed by MEIA (IMX/Abbot). The comparison between HIA and SP15-EIA, taking HIA as the standard methodology for determining immune status, showed that SP15-EIA is very specific and sensitive for detecting protecting antibodies (specificity, 100%; sensitivity, 98.20%). This study demonstrates that antibodies against the neutralizing domain represented by SP15 would be important in the memory response after natural infection and may be a good tool in the determination of the true immune status of patients with remote infection with regard to RV.
Similar articles
-
Comparison of a whole-virus enzyme immunoassay (EIA) with a peptide-based EIA for detecting rubella virus immunoglobulin G antibodies following rubella vaccination.J Clin Microbiol. 1993 Jun;31(6):1521-4. doi: 10.1128/jcm.31.6.1521-1524.1993. J Clin Microbiol. 1993. PMID: 8314994 Free PMC article.
-
Rubella reimmunization: comparative analysis of the immunoglobulin G response to rubella virus vaccine in previously seronegative and seropositive individuals.J Clin Microbiol. 1996 Sep;34(9):2210-8. doi: 10.1128/jcm.34.9.2210-2218.1996. J Clin Microbiol. 1996. PMID: 8862587 Free PMC article.
-
Characterization of rubella virus-specific antibody responses by using a new synthetic peptide-based enzyme-linked immunosorbent assay.J Clin Microbiol. 1992 Jul;30(7):1841-7. doi: 10.1128/jcm.30.7.1841-1847.1992. J Clin Microbiol. 1992. PMID: 1629342 Free PMC article.
-
Laboratory diagnosis of rubella virus infections.Can Med Assoc J. 1973 Apr 7;108(7):894-5 passim. Can Med Assoc J. 1973. PMID: 4581796 Free PMC article. Review. No abstract available.
-
Rubella in pregnancy.Obstet Gynecol Annu. 1974;3(0):345-75. Obstet Gynecol Annu. 1974. PMID: 4608493 Review. No abstract available.
Cited by
-
T Lymphocytes as Measurable Targets of Protection and Vaccination Against Viral Disorders.Int Rev Cell Mol Biol. 2019;342:175-263. doi: 10.1016/bs.ircmb.2018.07.006. Epub 2018 Oct 24. Int Rev Cell Mol Biol. 2019. PMID: 30635091 Free PMC article. Review.
-
Characterization of rubella-specific humoral immunity following two doses of MMR vaccine using proteome microarray technology.PLoS One. 2017 Nov 16;12(11):e0188149. doi: 10.1371/journal.pone.0188149. eCollection 2017. PLoS One. 2017. PMID: 29145521 Free PMC article.
-
Study protocol for a phase 1/2, single-centre, double-blind, double-dummy, randomized, active-controlled, age de-escalation trial to assess the safety, tolerability and immunogenicity of a measles and rubella vaccine delivered by a microneedle patch in healthy adults (18 to 40 years), measles and rubella vaccine-primed toddlers (15 to 18 months) and measles and rubella vaccine-naïve infants (9 to 10 months) in The Gambia [Measles and Rubella Vaccine Microneedle Patch Phase 1/2 Age De-escalation Trial].Trials. 2022 Sep 14;23(1):775. doi: 10.1186/s13063-022-06493-5. Trials. 2022. PMID: 36104719 Free PMC article.
-
Rubella.Lancet. 2015 Jun 6;385(9984):2297-307. doi: 10.1016/S0140-6736(14)60539-0. Epub 2015 Jan 8. Lancet. 2015. PMID: 25576992 Free PMC article. Review.
References
-
- Centers for Disease Control. Increase in rubella and congenital rubella. Morb Mortal Wkly Rep. 1990;40:93–99. - PubMed
-
- Cordoba P, Nates S, Zapata M, Mahony J. Kinetics of specific IgM response in postnatal rubella infection by ion exchange chromatography-HAI. J Virol Methods. 1991;34:31–43. - PubMed
-
- Cordoba P, Grutadauria S, Cuffini C, Zapata M. Different affinity of monoclonal antibodies for conserved neutralizing epitopes on two strains of Rubella virus. Viral Immunol. 1997;10:103–110. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources